Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • DKFZ Publication Database  (1)
  • IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES  (1)
  • 1
    Keywords: NECROSIS-FACTOR-ALPHA ; NATURAL-KILLER-CELLS ; HUMAN DENDRITIC CELLS ; TOLL-LIKE RECEPTORS ; COLONY-STIMULATING FACTOR ; ISOLATED LIMB PERFUSION ; REGULATORY T-CELLS ; PHASE-I TRIAL ; DEPENDENT CELLULAR CYTOTOXICITY ; IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES
    Abstract: During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
    Type of Publication: Journal article published
    PubMed ID: 25537519
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...